Skip to main content
Erschienen in: CNS Drugs 9/2001

01.09.2001 | Review Article

Comparative Efficacy and Tolerability of Drug Treatments for Bipolar Disorder

verfasst von: Dr Stephen M. Strakowski, Melissa P. DelBello, Caleb M. Adler

Erschienen in: CNS Drugs | Ausgabe 9/2001

Einloggen, um Zugang zu erhalten

Abstract

Lithium has been the backbone of treatment for bipolar disorder for several decades, although recent advances have identified a number of other medications that have efficacy in treating various phases of the illness. These include the antiepileptic drugs valproate semisodium (divalproex sodium) and carbamazepine and some new antiepileptic drugs (e.g. lamotrigine and topiramate), and the atypical antipsychotics (e.g. olanzapine, clozapine and risperidone). Conventional antipsychotics continue to be used frequently in bipolar disorder, although they may be somewhat less effective than other treatments. Otherwise, to date, none of these treatments have been shown to be consistently more effective than any other, so that drug adverse effects and tolerability often dictate which agents are used in an individual patient.
Drugs commonly used for the treatment of bipolar disorder are generally tolerated by most patients in large samples. However, the unique adverse effect signature of a drug will often suggest that it will be less tolerable in some patients than in others. Identifying a specific treatment for a specific patient requires a careful individualised assessment of the risk of adverse effects for that patient’s unique circumstances.
Literatur
1.
Zurück zum Zitat Janicak PG, Bresnahan DB, Sharma R, et al. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988; 8: 33–7PubMed Janicak PG, Bresnahan DB, Sharma R, et al. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988; 8: 33–7PubMed
2.
Zurück zum Zitat Poolsup N, Po ALW, de Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 2000; 25(2): 139–56PubMedCrossRef Poolsup N, Po ALW, de Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 2000; 25(2): 139–56PubMedCrossRef
3.
Zurück zum Zitat Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999 Aug; 156(8): 1264–6PubMed Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999 Aug; 156(8): 1264–6PubMed
4.
Zurück zum Zitat Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990 Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990
5.
Zurück zum Zitat Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997 Jan; 54(1): 37–42PubMedCrossRef Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997 Jan; 54(1): 37–42PubMedCrossRef
6.
Zurück zum Zitat Strakowski S, McElroy S, Keck P. Clinical efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Halbreich U, Montgomery S, editors. Pharmacotherapy for mood, anxiety and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 143–57 Strakowski S, McElroy S, Keck P. Clinical efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Halbreich U, Montgomery S, editors. Pharmacotherapy for mood, anxiety and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 143–57
7.
Zurück zum Zitat Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14(6): 339–43PubMedCrossRef Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14(6): 339–43PubMedCrossRef
8.
Zurück zum Zitat Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998 May–Jun; 21(3): 176–80PubMed Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998 May–Jun; 21(3): 176–80PubMed
9.
Zurück zum Zitat Zornberg GL, Pope Jr HG. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993 Dec; 13(6): 397–408PubMedCrossRef Zornberg GL, Pope Jr HG. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993 Dec; 13(6): 397–408PubMedCrossRef
10.
Zurück zum Zitat Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100: 406–17PubMedCrossRef Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100: 406–17PubMedCrossRef
11.
Zurück zum Zitat Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60Suppl. 2: 77–84PubMed Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60Suppl. 2: 77–84PubMed
12.
Zurück zum Zitat Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987 Mar; 48(3): 89–93PubMed Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987 Mar; 48(3): 89–93PubMed
13.
Zurück zum Zitat Small J, Klapper M, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991 Oct; 48(10): 915–21PubMedCrossRef Small J, Klapper M, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991 Oct; 48(10): 915–21PubMedCrossRef
14.
Zurück zum Zitat Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153: 198–204PubMedCrossRef Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153: 198–204PubMedCrossRef
15.
Zurück zum Zitat Greil W, Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders — a randomised study. J Affect Disord 1997; 43(2): 151–61PubMedCrossRef Greil W, Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders — a randomised study. J Affect Disord 1997; 43(2): 151–61PubMedCrossRef
16.
Zurück zum Zitat Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar disorder. Acta Psychiatr Scand 1992; 85: 114–8PubMedCrossRef Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar disorder. Acta Psychiatr Scand 1992; 85: 114–8PubMedCrossRef
17.
Zurück zum Zitat Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470–8PubMedCrossRef Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470–8PubMedCrossRef
18.
Zurück zum Zitat Freeman T, Clothier J, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992 Jan; 149(1): 108–11PubMed Freeman T, Clothier J, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992 Jan; 149(1): 108–11PubMed
19.
Zurück zum Zitat Bowden C, Brugger A, Swann A, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994 Mar 23–30; 271(12): 918–24PubMedCrossRef Bowden C, Brugger A, Swann A, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994 Mar 23–30; 271(12): 918–24PubMedCrossRef
20.
Zurück zum Zitat Bowden C, Calabrese JR, McElroy S, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry May 2000; 57: 481–9CrossRef Bowden C, Calabrese JR, McElroy S, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry May 2000; 57: 481–9CrossRef
21.
Zurück zum Zitat Prien R, Point P, Caffey E, et al. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972 Feb; 26: 146–53PubMedCrossRef Prien R, Point P, Caffey E, et al. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972 Feb; 26: 146–53PubMedCrossRef
22.
Zurück zum Zitat Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Arch Gen Psychiatry 1975 Oct; 32: 1310–8PubMedCrossRef Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Arch Gen Psychiatry 1975 Oct; 32: 1310–8PubMedCrossRef
23.
Zurück zum Zitat Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania. Arch Gen Psychiatry 1975 Jan; 32: 34–42PubMedCrossRef Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania. Arch Gen Psychiatry 1975 Jan; 32: 34–42PubMedCrossRef
24.
Zurück zum Zitat Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000 Mar; 12(1): 5–10PubMed Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000 Mar; 12(1): 5–10PubMed
25.
Zurück zum Zitat Post RM, Pazzaglia PJ, Ketter TA, et al. Carbamazepine and nimodipine in refractory bipolar illness: efficacy and mechanisms. In: Halbreich U, Montgomery S, editors. Pharmacotherapy for mood, anxiety and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 77–110 Post RM, Pazzaglia PJ, Ketter TA, et al. Carbamazepine and nimodipine in refractory bipolar illness: efficacy and mechanisms. In: Halbreich U, Montgomery S, editors. Pharmacotherapy for mood, anxiety and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 77–110
26.
Zurück zum Zitat Keck Jr PE, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59Suppl. 6: 74–81PubMed Keck Jr PE, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59Suppl. 6: 74–81PubMed
27.
Zurück zum Zitat McElroy SL, Keck Jr PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48: 539–57PubMedCrossRef McElroy SL, Keck Jr PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48: 539–57PubMedCrossRef
28.
Zurück zum Zitat Emrich HM. Studies with oxcarbazepine (Trileptal) in acute mania. In: Emrich H, Schiwy W, Silverstone T, editors. Carbamazepine and oxcarbazepine in psychiatry. London: CNS Publishers, 1990: 83–8 Emrich HM. Studies with oxcarbazepine (Trileptal) in acute mania. In: Emrich H, Schiwy W, Silverstone T, editors. Carbamazepine and oxcarbazepine in psychiatry. London: CNS Publishers, 1990: 83–8
29.
Zurück zum Zitat Müller AA, Stoll KD. Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany. In: ai]Emrich_HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984: 134–47 Müller AA, Stoll KD. Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany. In: ai]Emrich_HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984: 134–47
30.
Zurück zum Zitat Emrich HM, Dose M, vonZerssen D. The useof sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243–50PubMedCrossRef Emrich HM, Dose M, vonZerssen D. The useof sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243–50PubMedCrossRef
31.
Zurück zum Zitat Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology. Washington, DC: American Psychiatric Press Inc., 1997 Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology. Washington, DC: American Psychiatric Press Inc., 1997
32.
Zurück zum Zitat Britton JW, So EL. Selection of antiepileptic drugs: a practical approach. Mayo Clin Proc 1996; 71: 778–6PubMedCrossRef Britton JW, So EL. Selection of antiepileptic drugs: a practical approach. Mayo Clin Proc 1996; 71: 778–6PubMedCrossRef
33.
Zurück zum Zitat Gandelman MS. Review of carbamazepine-induced hyponatremia. Prog Neuropsychopharmacol Biol Psychiatry 1994 Mar; 8(2): 211–33CrossRef Gandelman MS. Review of carbamazepine-induced hyponatremia. Prog Neuropsychopharmacol Biol Psychiatry 1994 Mar; 8(2): 211–33CrossRef
34.
Zurück zum Zitat Albani F, Riva R, Baruzzi A. Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 1995; 28: 235–44PubMedCrossRef Albani F, Riva R, Baruzzi A. Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 1995; 28: 235–44PubMedCrossRef
35.
Zurück zum Zitat Sobotka JL, Alexander B, Cook BL. A review of carbamazepine’s hematologic reactions and monitoring recommendations. DICP 1990 Dec; 24(12): 1214–9PubMed Sobotka JL, Alexander B, Cook BL. A review of carbamazepine’s hematologic reactions and monitoring recommendations. DICP 1990 Dec; 24(12): 1214–9PubMed
36.
Zurück zum Zitat Van Amelsvoort T, Bakshi T, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994 Jan–Feb; 35(1): 181–8PubMedCrossRef Van Amelsvoort T, Bakshi T, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994 Jan–Feb; 35(1): 181–8PubMedCrossRef
38.
Zurück zum Zitat Okuma T, Inanaga K, Otsuki S, et al. Comparison of the anti-manic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979; 66(3): 211–7CrossRef Okuma T, Inanaga K, Otsuki S, et al. Comparison of the anti-manic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979; 66(3): 211–7CrossRef
39.
Zurück zum Zitat Grossi E, Sacchetti E, Vita A, et al. Carbamazepine versus chlorpromazine in mania: a double blind trial. In: Emrich HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984: 177–87 Grossi E, Sacchetti E, Vita A, et al. Carbamazepine versus chlorpromazine in mania: a double blind trial. In: Emrich HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984: 177–87
40.
Zurück zum Zitat Pope Jr HG, McElroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48: 62–8PubMedCrossRef Pope Jr HG, McElroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48: 62–8PubMedCrossRef
41.
Zurück zum Zitat Keck Jr PE, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993 Aug; 54(8): 305–8PubMed Keck Jr PE, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993 Aug; 54(8): 305–8PubMed
42.
Zurück zum Zitat Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993 Nov 4; 329(19): 1383–8PubMedCrossRef Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993 Nov 4; 329(19): 1383–8PubMedCrossRef
43.
Zurück zum Zitat Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000 Sep; 41(2): 163–7PubMedCrossRef Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000 Sep; 41(2): 163–7PubMedCrossRef
44.
Zurück zum Zitat Rasgon N, Altshuler L, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000 Mar; 61(3): 173–8PubMedCrossRef Rasgon N, Altshuler L, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000 Mar; 61(3): 173–8PubMedCrossRef
45.
Zurück zum Zitat Jennings H, Romanelli F. The use of valproic acid in HIV-positive patients. Ann Pharmacother 1999 Oct; 33: 1113–6PubMedCrossRef Jennings H, Romanelli F. The use of valproic acid in HIV-positive patients. Ann Pharmacother 1999 Oct; 33: 1113–6PubMedCrossRef
46.
Zurück zum Zitat McElroy SL, Keck P, Stanton S, et al. Arandomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996 Apr; 57(4): 142–6PubMed McElroy SL, Keck P, Stanton S, et al. Arandomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996 Apr; 57(4): 142–6PubMed
47.
Zurück zum Zitat Tohen M, Baker RW, Altshuler L, et al. Olanzapine versus divalproex for the treatment of acute mania [abstract]. European College of Neuropsychopharmacology Annual Meeting; 2000 Sep 9–13; Munich Tohen M, Baker RW, Altshuler L, et al. Olanzapine versus divalproex for the treatment of acute mania [abstract]. European College of Neuropsychopharmacology Annual Meeting; 2000 Sep 9–13; Munich
48.
Zurück zum Zitat Labbate L, Rubey R. Lamotrigine for treatment-refractory bipolar disorder [letter]. Am J Psychiatry 1997; 154: 1317PubMed Labbate L, Rubey R. Lamotrigine for treatment-refractory bipolar disorder [letter]. Am J Psychiatry 1997; 154: 1317PubMed
49.
Zurück zum Zitat Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997 Dec; 58(12): 522–7PubMedCrossRef Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997 Dec; 58(12): 522–7PubMedCrossRef
50.
Zurück zum Zitat Calabrese J, Fatemi S, Woyshville M. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter]. Am J Psychiatry 1996; 153: 1236PubMed Calabrese J, Fatemi S, Woyshville M. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter]. Am J Psychiatry 1996; 153: 1236PubMed
51.
Zurück zum Zitat Calabrese JR, Rapport DJ, Shelton MD, et al. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 1998 Oct; 38(3): 185–91PubMedCrossRef Calabrese JR, Rapport DJ, Shelton MD, et al. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 1998 Oct; 38(3): 185–91PubMedCrossRef
52.
Zurück zum Zitat Kusumakar V, Yatham L. Lamotrigine treatment of rapid cycling bipolar disorder [letter]. Am J Psychiatry 1997; 154: 1171–2PubMed Kusumakar V, Yatham L. Lamotrigine treatment of rapid cycling bipolar disorder [letter]. Am J Psychiatry 1997; 154: 1171–2PubMed
53.
Zurück zum Zitat Waiden J, Hesslinger B, van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996 Sep; 29(5): 193–5CrossRef Waiden J, Hesslinger B, van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996 Sep; 29(5): 193–5CrossRef
54.
Zurück zum Zitat Fogelson D, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 1997; 58: 271–3PubMedCrossRef Fogelson D, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 1997; 58: 271–3PubMedCrossRef
55.
Zurück zum Zitat Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185–9PubMedCrossRef Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185–9PubMedCrossRef
56.
Zurück zum Zitat Kotier M, Matar M. Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998; 21: 65–7 Kotier M, Matar M. Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998; 21: 65–7
57.
Zurück zum Zitat Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999 Jul; 156: 1019–23PubMed Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999 Jul; 156: 1019–23PubMed
58.
Zurück zum Zitat Weisler R, Risner ME, Ascher J, et al. Use of lamotrigine in the treatment of bipolar disorder [abstract]. In: The American Psychiatric Association Annual Meeting New Research Program and Abstracts. Washington, DC: American Psychiatric Association, 1994 May: 216 Weisler R, Risner ME, Ascher J, et al. Use of lamotrigine in the treatment of bipolar disorder [abstract]. In: The American Psychiatric Association Annual Meeting New Research Program and Abstracts. Washington, DC: American Psychiatric Association, 1994 May: 216
59.
Zurück zum Zitat Suppes T, Brown E, McElroy S, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53: 95–8PubMedCrossRef Suppes T, Brown E, McElroy S, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53: 95–8PubMedCrossRef
60.
Zurück zum Zitat Bowden CL, Calabrese JR, McElroy SL, et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953–8PubMedCrossRef Bowden CL, Calabrese JR, McElroy SL, et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953–8PubMedCrossRef
61.
Zurück zum Zitat Frye MA, Ketter TA, Kimbrell TA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–14PubMedCrossRef Frye MA, Ketter TA, Kimbrell TA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–14PubMedCrossRef
62.
Zurück zum Zitat Anand A, Oren DA, Berman RM, et al. Lamotrigine treatment of lithium failure in outpatient mania — a double-blind, placebo-controlled trial [abstract]. In: Soares JC, Gershon S, editors. Bipolar disorders abstract book. Third International Conference on Bipolar Disorder; 1999 Jun 17–19; Pittsburgh (PA).Copenhagen: Munksgaard, 1999: 23 Anand A, Oren DA, Berman RM, et al. Lamotrigine treatment of lithium failure in outpatient mania — a double-blind, placebo-controlled trial [abstract]. In: Soares JC, Gershon S, editors. Bipolar disorders abstract book. Third International Conference on Bipolar Disorder; 1999 Jun 17–19; Pittsburgh (PA).Copenhagen: Munksgaard, 1999: 23
63.
Zurück zum Zitat Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Am J Psychiatry 1999 Feb; 60: 79–88 Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Am J Psychiatry 1999 Feb; 60: 79–88
64.
Zurück zum Zitat Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000 Jul; 60(1): 23–33PubMedCrossRef Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000 Jul; 60(1): 23–33PubMedCrossRef
65.
Zurück zum Zitat Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998 Nov; 25(4): S14–8PubMed Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998 Nov; 25(4): S14–8PubMed
66.
Zurück zum Zitat Gilman JT. Lamotrigine: an antiepileptic agent for the treatment of partial seizures. Ann Pharmacother 1995 Feb; 29(2): 144–51PubMed Gilman JT. Lamotrigine: an antiepileptic agent for the treatment of partial seizures. Ann Pharmacother 1995 Feb; 29(2): 144–51PubMed
67.
Zurück zum Zitat Bozikas V, Vartzopoulos D, Phocas C, et al. Lamotrigine-induced rash after sun exposure [letter]. Am J Psychiatry 1999; 156: 2015–6PubMed Bozikas V, Vartzopoulos D, Phocas C, et al. Lamotrigine-induced rash after sun exposure [letter]. Am J Psychiatry 1999; 156: 2015–6PubMed
68.
Zurück zum Zitat Isojärvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Arch Neurol 2000 Jul; 57(7): 1064–8PubMedCrossRef Isojärvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Arch Neurol 2000 Jul; 57(7): 1064–8PubMedCrossRef
69.
Zurück zum Zitat Husain AM, Carwile ST, Miller PP, et al. Improved sexual function in three men taking lamotrigine for epilepsy. South Med J 2000 Mar; 93(3): 335–6PubMed Husain AM, Carwile ST, Miller PP, et al. Improved sexual function in three men taking lamotrigine for epilepsy. South Med J 2000 Mar; 93(3): 335–6PubMed
70.
Zurück zum Zitat Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245–51PubMedCrossRef Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245–51PubMedCrossRef
71.
Zurück zum Zitat Chengappa KNR, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1:42–53PubMedCrossRef Chengappa KNR, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1:42–53PubMedCrossRef
72.
Zurück zum Zitat Gordon A, Price L. Mood stabilization and weight loss with topiramate [letter]. Am J Psychiatry 1999; 156: 968–9PubMed Gordon A, Price L. Mood stabilization and weight loss with topiramate [letter]. Am J Psychiatry 1999; 156: 968–9PubMed
73.
Zurück zum Zitat Calabrese JR, Keck Jr PE, McElroy SL, et al. Topiramate in severe treatment-refractory mania [abstract]. In: The American Psychiatric Association Annual Meeting; 1998 May 30–Jun 4; Toronto, Canada. Washington, DC: American Psychiatric Association, 1998: 121–2 Calabrese JR, Keck Jr PE, McElroy SL, et al. Topiramate in severe treatment-refractory mania [abstract]. In: The American Psychiatric Association Annual Meeting; 1998 May 30–Jun 4; Toronto, Canada. Washington, DC: American Psychiatric Association, 1998: 121–2
74.
Zurück zum Zitat Normann C, Langosch J, Schaerer L, et al.Treatmentof acute mania with topiramate [letter]. Am J Psychiatry 1999; 156: 2014PubMed Normann C, Langosch J, Schaerer L, et al.Treatmentof acute mania with topiramate [letter]. Am J Psychiatry 1999; 156: 2014PubMed
75.
Zurück zum Zitat Kusumakar V, Kakshmi N, Yatham MB, et al. Topiramate in rapid cycling bipolar women [abstract]. In: The American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington, DC. Washington, DC: American Psychiatric Association, 1999: 200 Kusumakar V, Kakshmi N, Yatham MB, et al. Topiramate in rapid cycling bipolar women [abstract]. In: The American Psychiatric Association Annual Meeting; 1999 May 15–20; Washington, DC. Washington, DC: American Psychiatric Association, 1999: 200
76.
Zurück zum Zitat McElroy S, Suppes T, Keck P, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025–33PubMedCrossRef McElroy S, Suppes T, Keck P, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025–33PubMedCrossRef
77.
Zurück zum Zitat Hussain M. Treatment of bipolar depression with topiramate [abstract]. 38th Annual Meeting of American College of Neuropsychopharmacology; 1999 Dec 12–16; Acapulco Hussain M. Treatment of bipolar depression with topiramate [abstract]. 38th Annual Meeting of American College of Neuropsychopharmacology; 1999 Dec 12–16; Acapulco
78.
Zurück zum Zitat Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37Suppl. 2: S18–22PubMedCrossRef Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37Suppl. 2: S18–22PubMedCrossRef
79.
Zurück zum Zitat Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000 May; 61(5): 368–72PubMedCrossRef Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000 May; 61(5): 368–72PubMedCrossRef
80.
Zurück zum Zitat Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53(5 Suppl. 2): S53–67PubMed Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53(5 Suppl. 2): S53–67PubMed
81.
Zurück zum Zitat Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997 Nov–Dec; 19(6): 1294–308PubMedCrossRef Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997 Nov–Dec; 19(6): 1294–308PubMedCrossRef
82.
Zurück zum Zitat Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998 Jun; 7(3): 207–11PubMedCrossRef Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998 Jun; 7(3): 207–11PubMedCrossRef
83.
Zurück zum Zitat Hamer HM, Knake S, Schomburg U, et al. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 Jan 11; 54(1): 230–2PubMedCrossRef Hamer HM, Knake S, Schomburg U, et al. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 Jan 11; 54(1): 230–2PubMedCrossRef
84.
Zurück zum Zitat Solomon GE. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 Aug 22; 55(4): 606PubMedCrossRef Solomon GE. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 Aug 22; 55(4): 606PubMedCrossRef
85.
Zurück zum Zitat Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2 (3 Pt 2): 249–55PubMedCrossRef Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2 (3 Pt 2): 249–55PubMedCrossRef
86.
Zurück zum Zitat Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. Am J Psychiatry 1999 Dec; 156(12): 2014–5PubMed Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. Am J Psychiatry 1999 Dec; 156(12): 2014–5PubMed
87.
Zurück zum Zitat Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60: 759–62PubMedCrossRef Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60: 759–62PubMedCrossRef
88.
Zurück zum Zitat Kanba S, Yagi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 707–15PubMedCrossRef Kanba S, Yagi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 707–15PubMedCrossRef
89.
Zurück zum Zitat Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000 Jan; 9(1): 65–70PubMedCrossRef Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000 Jan; 9(1): 65–70PubMedCrossRef
90.
Zurück zum Zitat Charles CL, Stoesz L, Tollefson G. Zonisamide-induced mania. Psychosomatics 1990; 31(2): 214–7PubMedCrossRef Charles CL, Stoesz L, Tollefson G. Zonisamide-induced mania. Psychosomatics 1990; 31(2): 214–7PubMedCrossRef
91.
Zurück zum Zitat Keck Jr PE, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61Suppl. 4: 33–8PubMed Keck Jr PE, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61Suppl. 4: 33–8PubMed
92.
Zurück zum Zitat McElroy SL, Keck Jr PE, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 3: 14–26 McElroy SL, Keck Jr PE, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 3: 14–26
93.
Zurück zum Zitat Müller-Oerlinghausen B, Retzow A, Henn FA, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled multicenter study. J Clin Psychopharmacol 2000; 20: 195–203PubMedCrossRef Müller-Oerlinghausen B, Retzow A, Henn FA, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled multicenter study. J Clin Psychopharmacol 2000; 20: 195–203PubMedCrossRef
94.
Zurück zum Zitat Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981; 64: 226–37PubMedCrossRef Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981; 64: 226–37PubMedCrossRef
95.
Zurück zum Zitat Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984; 25: 135–8PubMedCrossRef Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984; 25: 135–8PubMedCrossRef
96.
Zurück zum Zitat Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999 May; 156(5): 702–9PubMed Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999 May; 156(5): 702–9PubMed
97.
Zurück zum Zitat Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841–9PubMedCrossRef Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841–9PubMedCrossRef
98.
Zurück zum Zitat Tohen M, Chengappa KNR, Suppes TR, et al. Efficacy of olanzapine added to valproate or lithium in the treatment of bipolar I disorder [abstract]. American Psychiatric Association Annual Meeting; 2000 May 13–18; Chicago (IL). Washington, DC: American Psychiatric Association, 2000 Tohen M, Chengappa KNR, Suppes TR, et al. Efficacy of olanzapine added to valproate or lithium in the treatment of bipolar I disorder [abstract]. American Psychiatric Association Annual Meeting; 2000 May 13–18; Chicago (IL). Washington, DC: American Psychiatric Association, 2000
99.
Zurück zum Zitat Tohen MF, Jacobs TG, Gannon KS, et al. Olanzapine: acute and long-term efficacy in bipolar I patients. Eur Neuropsychopharmacol 1999; 9Suppl. 5: S247 Tohen MF, Jacobs TG, Gannon KS, et al. Olanzapine: acute and long-term efficacy in bipolar I patients. Eur Neuropsychopharmacol 1999; 9Suppl. 5: S247
100.
Zurück zum Zitat Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998 Oct 15; 44(8): 778–83PubMedCrossRef Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998 Oct 15; 44(8): 778–83PubMedCrossRef
101.
Zurück zum Zitat Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999 Jan; 174: 23–30PubMedCrossRef Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999 Jan; 174: 23–30PubMedCrossRef
102.
Zurück zum Zitat Sachs GS. Safety and efficacy of risperidone vs. placebo vs. haloperidol as add-on therapy to mood stabilizers in treatment of the manic phase of bipolar disorder [abstract; board 35]. 38th Annual Meeting of American College of Neuropsychopharmacology; 1999 Dec 12–16; Acapulco Sachs GS. Safety and efficacy of risperidone vs. placebo vs. haloperidol as add-on therapy to mood stabilizers in treatment of the manic phase of bipolar disorder [abstract; board 35]. 38th Annual Meeting of American College of Neuropsychopharmacology; 1999 Dec 12–16; Acapulco
103.
Zurück zum Zitat Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215–28PubMedCrossRef Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215–28PubMedCrossRef
104.
Zurück zum Zitat Davis JM, Janicak PG. Risperidone: a new, novel (and better?) antipsychotic. Psychiatric Ann 1996 Feb; 26(2): 1–10 Davis JM, Janicak PG. Risperidone: a new, novel (and better?) antipsychotic. Psychiatric Ann 1996 Feb; 26(2): 1–10
105.
Zurück zum Zitat Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68PubMedCrossRef Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68PubMedCrossRef
106.
Zurück zum Zitat Frye MA, Ketter TA, Altshuler LL, et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91–110PubMedCrossRef Frye MA, Ketter TA, Altshuler LL, et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91–110PubMedCrossRef
107.
Zurück zum Zitat Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999 Aug; 156(8): 1164–9PubMed Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999 Aug; 156(8): 1164–9PubMed
108.
Zurück zum Zitat Zarate Jr CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411–7PubMed Zarate Jr CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411–7PubMed
109.
Zurück zum Zitat Barbini B, Scherillo P, Benedetti F, et al. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997; 12: 109–12PubMedCrossRef Barbini B, Scherillo P, Benedetti F, et al. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997; 12: 109–12PubMedCrossRef
110.
Zurück zum Zitat Calabrese JR, Kimmel SA, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759–64PubMed Calabrese JR, Kimmel SA, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759–64PubMed
111.
Zurück zum Zitat Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000 Jun; 157(6): 982–6PubMedCrossRef Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000 Jun; 157(6): 982–6PubMedCrossRef
112.
Zurück zum Zitat Lieberman J, Safferman A. Clinical profile of clozapine: adverse reactions and agranulocytosis. In: Lapierre Y, Jones B, editors. Clozapine in treatment-resistant schizophrenia. Royal Society of Medicine Services International Congress and Symposium Series, No. 185. London: Royal Society of Medicine Services Ltd., 1992 Jun Lieberman J, Safferman A. Clinical profile of clozapine: adverse reactions and agranulocytosis. In: Lapierre Y, Jones B, editors. Clozapine in treatment-resistant schizophrenia. Royal Society of Medicine Services International Congress and Symposium Series, No. 185. London: Royal Society of Medicine Services Ltd., 1992 Jun
113.
Zurück zum Zitat Munro J, O’Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999 Dec; 175: 576–80PubMedCrossRef Munro J, O’Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999 Dec; 175: 576–80PubMedCrossRef
114.
Zurück zum Zitat Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000 Jun; 157(6): 975–81PubMedCrossRef Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000 Jun; 157(6): 975–81PubMedCrossRef
115.
Zurück zum Zitat Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999; 11: 137–40PubMed Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999; 11: 137–40PubMed
116.
Zurück zum Zitat Dunayevich E, Strakowski SM. Seroquel in treatment-resistant mania. Am J Psychiatry 2000; 157: 1341PubMedCrossRef Dunayevich E, Strakowski SM. Seroquel in treatment-resistant mania. Am J Psychiatry 2000; 157: 1341PubMedCrossRef
117.
Zurück zum Zitat Zarate Jr CA, Rothschild A, Fletcher KE, et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000 Mar; 61(3): 185–9PubMedCrossRef Zarate Jr CA, Rothschild A, Fletcher KE, et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000 Mar; 61(3): 185–9PubMedCrossRef
118.
Zurück zum Zitat Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156(11): 1686–96PubMed Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156(11): 1686–96PubMed
119.
Zurück zum Zitat Keck Jr PE, Ice K. A three-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania [abstract]. The American Psychiatric Association Annual Meeting; 2000 May 13–18; Chicago (IL). Washington, DC: American Psychiatric Association, 2000: 116–7 Keck Jr PE, Ice K. A three-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania [abstract]. The American Psychiatric Association Annual Meeting; 2000 May 13–18; Chicago (IL). Washington, DC: American Psychiatric Association, 2000: 116–7
120.
Zurück zum Zitat Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996 May; 153(5): 592–606PubMed Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996 May; 153(5): 592–606PubMed
121.
Zurück zum Zitat Ortho-McNeil Pharmaceuticals. Topamax® product insert. Raritan (NJ): Ortho-McNeil Pharmaceuticals, 1999 Ortho-McNeil Pharmaceuticals. Topamax® product insert. Raritan (NJ): Ortho-McNeil Pharmaceuticals, 1999
122.
Zurück zum Zitat Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000 Jan; 182: 159–63PubMedCrossRef Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000 Jan; 182: 159–63PubMedCrossRef
123.
Zurück zum Zitat Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20: 399–403PubMedCrossRef Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20: 399–403PubMedCrossRef
124.
Zurück zum Zitat Trixler M, Tenyi T. Antipsychotic use in pregnancy: what are the best treatment options? Drug Saf 1997 Jun; 16(6): 403–10PubMedCrossRef Trixler M, Tenyi T. Antipsychotic use in pregnancy: what are the best treatment options? Drug Saf 1997 Jun; 16(6): 403–10PubMedCrossRef
125.
Zurück zum Zitat Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guidelines Series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr; Spec. No.: 1–104 Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guidelines Series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr; Spec. No.: 1–104
126.
Zurück zum Zitat Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998 Jan; 155(1): 12–21PubMed Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998 Jan; 155(1): 12–21PubMed
127.
Zurück zum Zitat Viguera AC, Cohen LS. The course and management of bipolar disorder during pregnancy. Psychopharmacol Bull 1998; 34: 339–46PubMed Viguera AC, Cohen LS. The course and management of bipolar disorder during pregnancy. Psychopharmacol Bull 1998; 34: 339–46PubMed
128.
Zurück zum Zitat Leibenluft E. Women and bipolar disorder: an update. Bull Menninger Clin 2000; 64: 5–17PubMed Leibenluft E. Women and bipolar disorder: an update. Bull Menninger Clin 2000; 64: 5–17PubMed
Metadaten
Titel
Comparative Efficacy and Tolerability of Drug Treatments for Bipolar Disorder
verfasst von
Dr Stephen M. Strakowski
Melissa P. DelBello
Caleb M. Adler
Publikationsdatum
01.09.2001
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 9/2001
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115090-00004

Weitere Artikel der Ausgabe 9/2001

CNS Drugs 9/2001 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.